2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005

IntelGenx Reports Results for the Nine Months Ended September 30, 2008 November 12, 2008

IntelGenx Corp. set to file NDA for antidepressant October 10, 2008

IntelGenx Welcomes New Chief Financial Officer, Paul Simmons September 5, 2008

IntelGenx Corp. and Cary Pharmaceuticals Inc. Announce Successful End-of-Phase II Meeting with FDA for Development of their Antidepressant CPI-300 July 30, 2008

IntelGenx Technologies Corp. Engages Auctus Capital Partners Inc. To Perform Investor Relations Activities June 3, 2008

IntelGenx Technologies Corp. Approved for trading on the TSX-Venture Exchange May 22, 2008

IntelGenx Corp. Forms Strategic Alliance with Dava Pharmaceuticals to Develop Cardiovascular Product Addressing a U.S. Market of $1.0 Billion April 14, 2008

IntelGenx Corp. and Cary Pharmaceuticals Confirm Agreement to Develop a Novel Antidepressant April 7, 2008

IntelGenx Technologies Corp. announces closing of private placement March 28, 2008

IntelGenx Corp. Forms Strategic Agreement with Azur Pharma to Develop Prenatal Vitamin Supplements Addressing a U.S. Market of $250 million January 7, 2008

About us

Product

R&D Services

Manufacturing Services

Partnering

Overview

Investors

More Links

© Copyright 2019. IntelGenx Corp. All Rights Reserved.

Powered By Q4 Inc. 5.35.1.5